L9277
Anti-Leukemia Inhibitory Factor antibody produced in goat
IgG fraction of antiserum, lyophilized powder
Synonym(s):
Anti-LIF
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
goat
Quality Level
conjugate
unconjugated
antibody form
IgG fraction of antiserum
antibody product type
primary antibodies
clone
polyclonal
form
lyophilized powder
species reactivity
human
technique(s)
neutralization: suitable
UniProt accession no.
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... LIF(3976)
General description
Leukemia inhibitory factor (LIF) is a pleotrophic glycoprotein that belongs to the IL6 family of cytokines. It is secreted by many cell types such as, fibroblasts, macrophages, T cells, monocytes, liver cells, osteoblasts and cells of endometrium. LIF interacts with a heterodimeric receptor composed of two subunits, gp130 and gp190. A variety of signal transduction pathways are triggered in response to LIF including ERK/MAPK, JAK1, PI3K, STAT3, Jun-cFos and NF-κB. The various functions of LIF include proliferation of adult human T cells, maintenance of pluripotency of embryonic stem cells and inhibition of leukemic ell differentiation. Reports also indicate the important role of LIF in lactation, tissue regeneration after brain and spinal cord injury, muscle regeneration and motor neuron functions.
Anti-Leukemia Inhibitory Factor recognizes human leukemia inhibitory factor. It shows no cross-reactivity with recombinant mouse LIF.
Anti-Leukemia Inhibitory Factor recognizes human leukemia inhibitory factor. It shows no cross-reactivity with recombinant mouse LIF.
Specificity
The antibody neutralizes the biological activity of recombinant human LIF.
Immunogen
recombinant human LIF expressed in E. coli
Application
Anti-Leukemia Inhibitory Factor antibody may be for immunoblotting a concentration of 1 μg/ml For ELISA a working concentration of 1 μg/ml is recommended. The antibody is suitable for neutralization reactions. For neutralization of LIF in SEK1, melanoma cell line, a concentration of 100 μg/ml was used.
Physical form
Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline
Preparation Note
Purified using protein G
Not finding the right product?
Try our Product Selector Tool.
related product
Product No.
Description
Pricing
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Mikio Tomida et al.
Oncogene, 23(3), 679-686 (2003-12-03)
We found that human melanoma SEKI and neuroepithelioma NAGAI cells, which are known to secrete high concentrations of leukemia inhibitory factor (LIF), also secrete high levels of hepatocyte growth factor (HGF). We therefore examined the role of LIF in HGF
Pin Li et al.
EMBO molecular medicine, 14(1), e14511-e14511 (2021-11-16)
In the course of our studies aiming to discover vascular bed-specific endothelial cell (EC) mitogens, we identified leukemia inhibitory factor (LIF) as a mitogen for bovine choroidal EC (BCE), although LIF has been mainly characterized as an EC growth inhibitor
L C Hunt et al.
Experimental cell research, 316(6), 1002-1009 (2009-12-08)
Leukemia inhibitory factor (LIF) is an important regulator of skeletal muscle regeneration and has been suggested to be mitogenic for myogenic cells because it has been shown to increase the quantity of myoblast cells grown in culture over extended periods
Sylvian Bauer et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 26(46), 12089-12099 (2006-11-17)
Although neural stem cells (NSCs) persist in various areas of the adult brain, their contribution to brain repair after injury is very limited. Treatment with exogenous growth factors can mitigate this limitation, suggesting that the brain environment is normally deficient
S M Metcalfe
Genes and immunity, 12(3), 157-168 (2011-03-04)
At the heart of lineage commitment within the adaptive immune response is the intrinsic genetic plasticity of the naive peripheral T lymphocyte (T cell). Primary activation by presentation of cognate antigen is coupled to rapid T-cell cycling and progressive epigenetic
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
